KYNAMRO
LOE Approachingmipomersen sodium
NDASUBCUTANEOUSSOLUTION
Approved
Jan 2013
Lifecycle
LOE Approaching
Competitive Pressure
25/100
Data completeness
2/8 — Basic
Drug data last refreshed 20m ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
KYNAMRO (mipomersen sodium) is an antisense oligonucleotide that reduces apolipoprotein B-100 production, lowering LDL cholesterol levels. It is indicated for patients with homozygous familial hypercholesterolemia (HoFH) as an adjunct to other lipid-lowering therapies. The drug targets a rare, severe genetic lipid disorder where standard treatments are often insufficient.
LOE Approaching3mo to LOE
With LOE approaching in 0.4 years, commercial teams face rapid portfolio transition; expect consolidation of sales infrastructure and shift toward lifecycle extension or product exit strategies.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
Patent cliff in less than a year — expect lifecycle management and generic defense hiring
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.